E
Edgar L. Milford
Researcher at Brigham and Women's Hospital
Publications - 225
Citations - 18072
Edgar L. Milford is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Transplantation & Antigen. The author has an hindex of 54, co-authored 223 publications receiving 16954 citations. Previous affiliations of Edgar L. Milford include Cornell University & University of Utah.
Papers
More filters
Journal ArticleDOI
Antigen-Independent Determinants of Cadaveric Kidney Transplant Failure
TL;DR: The hypothesis that the supply of viable donor nephrons and the physiologic demands of the transplant recipient are important determinants of long-term graft failure is supported.
Journal ArticleDOI
The pathology of transfusion-related acute lung injury.
TL;DR: The case of a previously well 58-year-old man who died of transfusion-related acute lung injury within 2 hours of the onset of pulmonary distress is reported, showing evidence of massive pulmonary edema with granulocyte aggregation within the pulmonary microvasculature and extravasation into alveoli.
Journal ArticleDOI
TCR usage in human and experimental demyelinating disease
TL;DR: Several investigators convened recently to assess current knowledge and provide guidelines for future research on T-cell Receptor usage in Human and Experimental Demyelineting Disease.
Journal ArticleDOI
Assessment of optimal size and composition of the U.S. National Registry of hematopoietic stem cell donors.
Craig Kollman,Esteban Abella,Robert L. Baitty,Patrick G. Beatty,Ranajit Chakraborty,Cindy L. Christiansen,Robert J. Hartzman,Carolyn Katovich Hurley,Edgar L. Milford,John A. Nyman,Thomas J. Smith,Galen E. Switzer,Randal K. Wada,Michelle Setterholm +13 more
TL;DR: Efforts to improve donor availability (especially among minorities) and to increase the number of patients with access to the NMDP Registry may prove to be more cost-effective means of increasing transplants.
Journal ArticleDOI
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
Jennifer R. Brown,Jennifer R. Brown,Haesook T. Kim,Shuli Li,Katherine Stephans,Katherine Stephans,David C. Fisher,David C. Fisher,Corey Cutler,Corey Cutler,Vincent T. Ho,Vincent T. Ho,Stephanie J. Lee,Stephanie J. Lee,Edgar L. Milford,Edgar L. Milford,Jerome Ritz,Jerome Ritz,Joseph H. Antin,Joseph H. Antin,Robert J. Soiffer,Robert J. Soiffer,John G. Gribben,John G. Gribben,Edwin P. Alyea,Edwin P. Alyea +25 more
TL;DR: NST using fludarabine and low-dose intravenous busulfan is a reasonable treatment option for patients with advanced CLL, but that NST earlier in the disease course will likely be needed to achieve long-term disease control in a high proportion of patients.